Director at CVS sells 7,500 shares in insider sale

A recent insider sale at CVS caught the attention of investors as Anne A. Finucane, a director at CVS, disposed of 7,500 shares of the company on 08-20-2025, amounting to an estimated $532,650. This transaction represented about 25.3% of the shares of this particular class of stock that they held. Subsequently, Finucane now retains ownership of 22,156 shares of this class of CVS stock.

Over the past 6 months, CVS insiders have engaged in 9 stock transactions on the open market. Among these trades, 1 was a purchase while 8 were sales. Notable among these transactions were Larry Robbins, who conducted 6 sales of 3,750,000 CVS shares, totaling an estimated $253,695,413. Alongside Finucane’s recent sale, James David Clark, the Senior Vice President, Controller & Chief Accounting Officer of CVS, divested 7,513 shares for around $498,487. In contrast, Guy P. Sansone, another insider, acquired 1,570 shares for approximately $100,009.

Monitoring insider transactions can provide valuable insights into a company’s financial health and potential future performance. If you wish to stay updated on such activities, consider utilizing Quiver Quantitative’s insider trading dashboard.

Furthermore, hedge fund activity surrounding CVS stock has also been noteworthy. In the recent quarter, 782 institutional investors increased their CVS holdings, while 1,026 reduced their positions. Major moves included FMR LLC adding 14,716,719 shares (+47.6%) to their CVS portfolio in Q2 2025, valued at around $1,015,159,276. Similarly, BLACKROCK, INC. augmented their holdings by 10,093,204 shares (+9.0%) in the same quarter, amounting to an estimated $696,229,211. On the flip side, Capital Research Global Investors shed 9,510,578 shares (-50.8%) from their CVS portfolio in Q2 2025, valuing at $656,039,670.

Members of Congress have also been involved in trading CVS stock. In the last 6 months, Congress members have executed 3 transactions, all being sales with no purchases reported. Representative Robert Bresnahan sold up to $15,000 on 05/15, Representative Jefferson Shreve sold up to $50,000 on 05/12, and Representative Julie Johnson sold up to $15,000 on 04/01.

Lastly, Wall Street analysts’ assessments of CVS stock have been positive, with 9 firms issuing buy ratings and none issuing sell ratings. Recent analyst ratings include Cantor Fitzgerald issuing an “Overweight” rating on 08/26/2025, Baird issuing an “Outperform” rating on 08/14/2025, and Jefferies issuing a “Buy” rating on 06/30/2025. With a median price target of $80.0, CVS has garnered favorable forecasts from various analysts.

To stay informed about analyst ratings and price targets for CVS, consider leveraging Quiver Quantitative’s CVS forecast page. However, it’s important to note that the content provided is for informational purposes only and should not be considered financial advice. Kindly refer to Quiver Quantitative’s disclaimers for further information.